Can a common prostate drug spare the eye during cataract surgery?

NCT ID NCT07743034

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial compares two prostate medications, tamsulosin and silodosin, to see how each affects the iris—the colored part of the eye—in men with benign prostatic hyperplasia (BPH). Both drugs can make the iris floppy and the pupil small, which complicates cataract surgery. The study will measure iris muscle changes using advanced eye imaging before and after three months of treatment. Men aged 50 and older with moderate BPH symptoms who have not used these drugs before may participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tamsulosin and silodosin
What this could lead to
If one drug proves safer for the iris, it could guide treatment choices for BPH and lower the risk of cataract surgery complications.
What could go wrong
This is a small, early-phase trial, so results may not apply broadly. Both drugs are known to affect the iris, and the study only measures anatomical changes, not actual surgical outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BENIGN PROSTATIC HYPERPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.